Guided Therapeutics (GTHP) Net Income towards Common Stockholders Growth (1y) (2011 - 2025)
Guided Therapeutics (GTHP) Net Income towards Common Stockholders Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -30.10% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 121.14% |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | -70.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -70.86% |
| Sep 30, 2025 | -13.44% |
| Jun 30, 2025 | -12.93% |
| Mar 31, 2025 | -4.99% |
| Dec 31, 2024 | -49.25% |
| Sep 30, 2024 | 3.49% |
| Jun 30, 2024 | 52.74% |
| Mar 31, 2024 | 54.49% |
| Dec 31, 2023 | 74.74% |
| Sep 30, 2023 | 31.97% |
| Jun 30, 2023 | -59.29% |
| Mar 31, 2023 | 8.15% |
| Dec 31, 2022 | -264.83% |
| Sep 30, 2022 | -1,966.67% |
| Jun 30, 2022 | 13.11% |
| Mar 31, 2022 | -84.44% |
| Dec 31, 2021 | -124.02% |
| Sep 30, 2021 | -103.34% |
| Jun 30, 2021 | 82.87% |
| Mar 31, 2021 | -121.06% |